Tricuktan - instructions for use, analogs, reviews and release forms (20 mg and 35 mg CF tablets) drugs for the treatment of angina pectoris, ischemic heart disease, tinnitus, dizziness in adults, children and pregnancy. Composition

In this article, you can read the instructions for using the drug Tricuktan. There are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors specialists on the use of Trikdutana in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogs of Triductan in the presence of existing structural analogs. Use for the treatment of angina pectoris, coronary heart disease, tinnitus, dizziness in adults, children, as well as during pregnancy and lactation. Composition of the preparation.

Tricuctan - antianginal and antihypoxic drug. The antihypoxic and anti-ischemic effect of the drug is based on the ability of Trimetazidine (the active substance of the drug Trikludtan) to influence cellular metabolism, to prevent the decrease in the level of ATP (a universal source of energy for all biochemical processes) inside cells in hypoxic conditions. The drug also contributes to the normalization of energy balance in cells and maintenance of cellular homeostasis by regulating the function of the ion channels of cell membranes. Under conditions of hypoxia, the drug inhibits the oxidation of fatty acids due to the inhibition of a specific enzyme and stimulates the processes of glucose oxidation. Optimizing the use of oxygen contributes to the retention of ATP stores in the cells of the heart muscle.

In addition to intracellular protection under conditions of hypoxia, the drug increases the protection of cell membranes, due to stimulation of the inclusion of phospholipids in the membrane. Tricuctan improves exercise tolerance, increases the coronary reserve, reduces angina attacks and the need for nitrates in patients with coronary heart disease.

The drug has a positive effect in patients with noise in the ears, hearing impairment, dizziness (including in patients with Meniere's disease and cerebral circulation disorders). In addition, the preparation improves the tolerability of vestibular samples. Trimetazidine normalizes the functional activity of the retina in patients suffering from chorioretinal vascular disorders. The drug does not change the heart rate and hemodynamics.

Composition

Trimetazidine dihydrochloride + excipients.

Pharmacokinetics

After oral administration, the drug is well absorbed in the gastrointestinal tract. Bioavailability of the drug is about 85%. The peak concentration of active substance in the blood plasma is observed after 5 hours after a single application of the drug. Stable plasma concentrations of the drug are achieved on day 3 of the drug. Trimetazidine is characterized by a low degree of binding to plasma proteins (no more than 17%).

Trimetazidine is not metabolized in the body, most of the drug is excreted by the kidneys. The half-life of the drug is 7 hours, in elderly patients - about 12 hours.Renal clearance of trimetazidine directly correlates with creatinine clearance.

Indications

• long-term treatment of angina pectoris;
• prevention of angina attacks (as a monotherapy or in combination with other drugs);
• chorioretinal disorders of ischemic origin;
• treatment of cochlear-vestibular disorders of ischemic origin, such as dizziness, tinnitus, hearing loss.

Forms of release

Tablets of 20 mg and 35 mg of MB.

Instructions for use and dosing regimen

The drug is intended for oral administration. Tablets are recommended to swallow whole, without chewing and not grinding, squeezed with enough liquid. To achieve maximum therapeutic effect the drug is recommended to be taken during meals. The duration of the course of treatment and the dose of the drug is determined by the attending physician individually.

Adults usually prescribed 20 mg of the drug (1 tablet of the drug Trikludtan) 3 times a day or 35 mg of the drug (1 tablet of the drug Trikdutan MB) 2 times a day.

Side effect

• nausea, vomiting;
• gastralgia (cramping pains in the epigastric region);
• stool disorder;
• dizziness;
• headache;
• fainting;
• congestion (redness) of the face and upper body;
• lowering blood pressure;
• sleep disorders;
• skin rash;
• itching;
• hives;
• asthenia (general weakness).

Contraindications

• increased individual sensitivity to the components of the drug;
• severe violations of kidney function (creatinine clearance less than 15 ml per minute);
• Parkinson's disease;
• Parkinsonism symptoms;
• tremor;
• restless legs syndrome;
• children and adolescents under the age of 18;
• pregnancy, lactation.

Application in pregnancy and lactation

Tricuktan should not be administered to women during pregnancy.

If you need to use the drug during lactation, you should consult your doctor and decide on the interruption of breastfeeding.

Use in children

Experience in the use of the drug in childhood is not available, so the drug is not used in pediatric practice.

Application in elderly patients

Tricuktan is used with caution in patients older than 75 years.

special instructions

Tricuktan should not be used in cases of unstable angina or myocardial infarction as primary therapy at the prehospital stage or in the first days of hospitalization.

In the event of an attack of unstable angina on the background of current therapy, it is necessary to review the course of the disease and adjust the treatment (medication and the possibility of revascularization).

Trimetazidine can cause or worsen the symptoms of parkinsonism (tremor, akinesia, hypertonic muscle), which must be regularly examined, especially in elderly patients. In case of doubt, patients should be referred to a neurologist for an appropriate examination.

When motor disorders such as Parkinson's symptoms, tremor, restless legs syndrome, unsteadiness of gait appear, it is necessary to cancel the drug. These cases are of low frequency and usually disappear after discontinuation of treatment, in most patients - within 4 months after stopping the administration of trimetazidine. If the symptoms of parkinsonism persist for more than 4 months after discontinuation of the drug, you should contact a neurologist.

Possible falls associated with unstable gait or arterial hypotension, especially in patients with the use of antihypertensive drugs.

Caution should be used in patients with moderate impairment of renal function and elderly people (over 75 years of age).

The presence of yellow dusk (E110) and ponso 4R (E124) in the dye preparation can cause allergic reactions.

Drug Interactions

The interaction of the drug Trikludtan with other drugs that would lead to a negative effect is not described.

The use of Trikuktana in combination with nitrates, beta-adrenergic blockers or calcium antagonists provides an additional therapeutic effect in patients with angina pectoris.

Trimetazidine can be administered in combination with heparin, vitamin K antagonists (without potentiating their action), as well as with ACE inhibitors, oral hypolipidemic drugs, acetylsalicylic acid.

Analogues of the drug Triductan

Structural analogs for the active substance:

• Angiosyl;
• Antisthenes;
• Deprenorm;
• Carditrim;
• Medarum;
• Predizin;
• Preductal;
• Precardard;
• Romekor;
• Tridoukard;
• Trimectal;
• Trimet;
• Trimetazide;
• Trimetazidine;
• Trimitard.

Analogues for the pharmacological group (antihypoxants and antioxidants):

• Actovegin;
• Astrox;
• Valeocorus Q10;
• Vixipine;
• Vitanam;
• Hypoxen;
• Histochrome;
• Dihydroquercetin;
• Dimephosphone;
• Carnitine;
• Carniffite;
• Confusamine;
• Qudesan;
• Laproth;
• Levocarnitine;
• Medomexi;
• Mexidant;
• Mexidol;
• Mexicor;
• Mexiprim;
• Mexicin;
• Metostabil;
• Mitomin;
• Neurocardia;
• Neurox;
• Neurolephone;
• Octolipen;
• Oliphen;
• Polythion;
• Proxipin;
• Rexod;
• Tiogamma;
• Tiotriazolin;
• Trekrezan;
• Cytochrome;
• Emoxibel;
• Emoxipine;
• Energet;
• Epigallocatechin;
• Ethoxydol;
• Echinochrome;
• Yantavit.

Response of a cardiologist

Tricuktan is an effective medicine for relieving pain in the heart. I use it as a symptomatic therapy for patients with stable angina pectoris. Its active active substance, trimetazidine, has a pronounced antihypoxic and antianginal effect. Its use contributes to an increase in blood flow to the heart muscle, which effectively reduces the negative impact of ischemia. It is important to understand that Tricuktan is intended solely for basic therapy - the drug can not be used to stop acute conditions.

Similar medicines:

Other medicines: